Sphingolipids are important components of cell structure and cell signaling. Both external and internal stimuli can alter levels of cellular sphingolipids by regulating enzyme activities associated with sphingolipid metabolism. Fumonisin B 1 , mycotoxin produced by Fusarium verticillioides, is a reportedly specific inhibitor of ceramide synthase. In order to test our hypothesis whether ceramide synthase inhibition by fumonisin B 1 alters other sphingolipidmetabolizing enzymes, we investigated the changes in free sphingoid bases and sphingomyelin (SM) and activities of key enzymes for their metabolism, sphingomyelinase (SMase), serine palmitoyltransferase (SPT), and sphingosine kinase (SPHK) in mouse liver. The hepatic free sphingoid bases increased significantly following five daily treatments with fumonisin B 1 in mice. The activity of acidic SMase was enhanced by fumonisin B 1 , accompanied with a decrease in liver SM content. The expression and activities of SPT and SPHK1 in liver increased significantly following fumonisin B 1 treatment. Another hepatotoxicant acetaminophen caused liver regeneration similar to fumonisin B 1 but did not produce similar effects on liver sphingolipid-metabolizing enymes, suggesting that activation of sphingolipid metabolism was not a consequence of hepatocye regeneration. Data suggest that ceramide synthase inhibition by fumonisin B 1 treatment stimulates sphingolipid-metabolizing systems to maintain a balance of cellular sphingolipids.
Sphingolipids are ubiquitous components of eukaryotic cell membrane structures, providing integrity to cellular membranes. There is increasing evidence for the involvement of sphingolipids in regulating various cellular functions, such as cell-cell interactions, cellular protein and receptor functions, membrane transport, and signal transduction (Prieschl and Baumruker, 2000) . Simple sphingolipid compounds, such as sphingosine and sphingosine-1-phosphate, have been shown to mediate cellular signal cascades of apoptosis and proliferation .
Since both complex sphingolipids and the free sphingoid bases have important structural and functional properties in the cell and fumonisin B 1 is reportedly a potent inhibitor of ceramide synthase (see below) causing a rapid accumulation of sphingosine (Wang et al., 1991) , the resultant effect on sphingolipid homeostasis after fumonisin B 1 treatment are worthy of investigation. Effect of fumonisin B 1 on sphingolipid-metabolizing enzymes other than ceramide synthase has not been adequately studied. As illustrated in Figure 1 , the sphingolipid synthesis starts with the condensation of L-serine and palmitoyl coenzyme A (palmitoyl-CoA) to 3-ketosphinganine, and its reduction to sphinganine in the endoplasmic reticulum. Serine palmitoyltransferase (SPT), a membrane-associated heterodimer consisting of two gene products, long-chain base (LCB) 1 and LCB2, is the rate-limiting enzyme for the sphingolipid synthesis (Hanada, 2003) . Ceramide is central molecule that serves as the precursor for all major sphingolipids, that is, sphingomyelin (SM), glucosylceramide, and more complex sphingolipids in eukaryotic cells, and sphingolipid metabolism involves different key enzymes (Hannun et al., 2001 ).
Fumonisin B 1 , a mycotoxin produced by Fusarium verticillioides, is reportedly a specific and potent inhibitor of ceramide synthase. The concentration of fumonisin B 1 to inhibit 50% of activity of ceramide synthase (IC 50 ) was estimated to be 0.1lM for rat liver microsomes (Wang et al., 1991) ; and the IC 50 was about 0.7lM for labeling of SM in neurons (Merrill et al., 1993) . Inhibition of ceramide synthesis following fumonisin B 1 exposure results in decrease of SM, other complex sphingolipids, and diacylglycerol (Wu et al., 1995; Yoo et al., 1996) , while free sphingoid bases and their 1-phosphates are increased . In yeast, fumonisin B 1 inhibited ceramide synthase without any effects on inositol phosphorylceramide synthase, phosphatidylinositol synthase, and choline kinase, though fumonisin B 1 decreased levels of these lipids (Wu et al., 1995) . Long-term incubation of NIH/3T3 fibroblasts with fumonisin B 1 inhibited ceramide synthase leading to decrease of sphingolipids and glycosphingolipid but increased the activities of three glycosyltransferases in the pathway of globotriaosylceramide (Gb 3 ) synthesis, while the activities of ganglioside 3 (GM 3 ) and SM synthase were not affected (Meivar-Levy et al., 1999) . We have recently reported 1 To whom correspondence should be addressed at: 10513 West 84th Terrace, Lenexa, KS 66214-1643. Fax: þ1 (913) 685-8856. E-mail: qhe@cydexinc.com. that activity of hepatic SPT was increased in response to fumonisin B 1 treatment in mouse liver . It is unknown whether other enzymes for sphingolipid metabolism are affected following fumonisin B 1 exposure.
Following fumonisin B 1 treatment, the cells undergo growth arrest and apoptosis (Jones et al., 2001; Sharma et al., 1997; Yoo et al., 1996) . Compensatory cellular proliferation was observed in liver and kidney after exposure of rodents to fumonisin B 1 Howard et al., 2001b . In some cases, fumonisin B 1 is mitogenic and antiapoptotic (Schroeder et al., 1994) . Due to its reportedly specific inhibition of ceramide biosynthesis, fumonisin B 1 has been used extensively to study the biological roles of ceramide and complex sphingolipids in different cell cultures (Le Stunff et al., 2002; Reiss et al., 2004) .
In the present study, we hypothesized that ceramide synthase inhibition by fumonisin B 1 will influence the enzymes involved in sphingoid base metabolism in order to reestablish the homeostasis of lipid messengers. Therefore, the activities of sphingomyelinase (SMase), SPT, and sphingosine kinase (SPHK) in mouse liver were analyzed after fumonisin B 1 treatment. We observed that the activities and expression of both hepatic SPT and SPHK were increased in response to fumonisin B 1 treatment. Fumonisin B 1 treatment resulted in enhanced activity of acidic but not neutral SMase (N-SMase). Results suggest that ceramide synthase inhibition by fumonisin B 1 is associated with perturbation of sphingolipid metabolism by other metabolizing enzymes, and in most cases, maximal effects on sphingolipid-metabolizing enzymes were observed at the relatively low dose of fumonisin B 1 .
Since induction of cellular enzymes may be related to liver regeneration, we compared the effect of another hepatotoxicant, acetaminophen, on the synthesis of sphiongolipid-metabolizing enzymes. Although acetaminophen caused liver regeneration to an extent comparable to that with fumonisin B 1 , the former had no influence on the synthesis of SPT subunits or SPHK1.
MATERIALS AND METHODS
Materials. Fumonisin B 1 (> 98% purity) was obtained from Program on Mycotoxins and Experimental Carcinogenesis (Tygerberg, South Africa). C 20 -sphinganine standard (D-erythro-C 20 -dihydro-sphingosine, 98% purity) was procured from Matreya Inc., (Pleasant Gap, PA). Polyclonal SPT antibody against an amino acid sequence corresponding to 121-238 residues of LCB1 (mouse origin) was from BD Biosciences (Rockville, MD). Polyclonal antibody against SPHK1 was purchased from Oncogen (San Diego, CA). All other reagents were purchased from Sigma-Aldrich Chemical Company Inc., (St Louis, MO), unless otherwise stated.
Animal treatments and sampling. Female mice were employed, as they are more sensitive to hepatotoxic effects of fumonisin B 1 than male counterparts (Howard et al., 2001a) . Six-weeks-old female C57BL/6N mice weighing about 22 g were procured from Harlan Laboratories (Indianapolis, IN). They were acclimatized for 1 week before experiments under controlled environmental conditions of 23°C and 65% relative humidity, with a 12-h light/dark cycle. Feed and water were provided ad libitum. Animals were treated with humane care following the Public Health Service Policy on Humane Care and Use of Laboratory Animals, and protocols were approved by the Institutional Animal Care and Use Committee.
Mice were divided randomly into four groups with five animals each. The mice were treated with daily sc injection of 0, 0.75, 2.25, or 6.75 mg/kg body weight fumonisin B 1 for 5 consecutive days. The doses of fumonisin B 1 were based on our previous study where a dose-dependent hepatopathy was observed (Tsunoda et al., 1998) . Sterilized phosphate buffered saline (PBS) was used as the solvent for fumonisin B 1 and for injecting control groups. During treatment, body weight, food, and water consumptions were recorded daily.
Twenty-four hours following the final fumonisin B 1 treatment, mice were sacrificed under halothane anesthesia. Livers were collected from each animal and weighed; aliquots of randomized liver tissue were frozen in liquid nitrogen and stored at ÿ 85°C until analysis.
Analysis of hepatic damage. The liver injury following fumonisin B 1 treatment was determined by estimation of plasma aniline aminotransferase (ALT) and aspartate aminotransferase (AST) activities and numeration of apoptotic hepatocytes in liver tissue. The activity of plasma ALT and AST was analyzed using a Hitachi 912 Automatic Analyzer (Roche Diagnostics, Indianapolis, IN). Liver tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned (4-5 lm) for terminal dUTP nick end labeling (TUNEL) with a peroxidase-based In Situ Cell Death Detection kit (Roche Diagnostics) as described previously (Sharma et al., 1997) .
Sphingolipid analysis. Free sphingosine and sphinganine of liver in basetreated lipid extracts were determined by high-performance liquid chromatography (HPLC) using a modification of the extraction methods described previously (Merrill et al., 1988) . Sphingoid bases were quantified based on the recovery of a C 20 -sphinganine standard (D-erythro-C 20 -dihydro-sphingosine). The HPLC apparatus and derivation procedure were similar to those indicated previously .
SM and SMase assay. SM was analyzed by a fluorescence-based method following enzymatic catalysis (He et al., 2002) . Livers were homogenized in 0.25% Triton X-100 in PBS (1:20) and centrifuged (10,000 3 g for 5 min). Aliquots of 20 ll supernatant were mixed with equal volumes of homogenizing buffer followed by heating at 70°C for 5 min to destroy endogenous enzymatic activity. Ten microliters of the supernatant was added to an enzyme cocktail consisting of 12.5 mU of Bacillus cereus SMase, 400 mU of alkaline phosphatase, 120 mU choline oxidase, 200 mU of horseradish peroxidase, and FUMONISIN ALTERS SPHINGOLIPID METABOLISM 389 20 nmol of 10-acetyl-3-dihydrophenoxazine, a sensitive fluorogenic probe for hydrogen peroxide (Amplex red reagent, Molecular Probes, Inc., Eugene, OR), in a reaction buffer (0.1M Tris-HCl, 10mM MgCl 2 , pH 7.4). For each sample, a negative control containing 10 ll of the sample and the same reaction mixture without SMase was employed. After 20 min incubation at 37°C, the microplate was read using a fluorescence reader (Molecular Devices Corp., Sunnyvale, CA), with the excitation and emission wavelengths set at 560 and 590 nm, respectively. SM contents were calculated from the difference in fluorescence between the test and the negative control samples by comparing with a standard curve.
The activity of SMase was determined using Amplex Red Sphingomyelinase Assay Kit according to the manufacturer's protocol (Molecular Probes). Frozen tissue was homogenized in a buffer containing 100mM Tris-HCl, 0.5% Triton X-100 (pH 7.4). The homogenate was then centrifuged at 10,000 3 g for 5 min, and the supernatant (50 lg protein) was used for SMase assay. The N-SMase activity was determined in 100 ll of reaction solutions containing 0.1M Tris-HCl (pH 7.4), 10mM MgCl 2 , 0.5mM SM, 0.2 U/ml choline oxidase, 2 U/ml horseradish peroxidase, 8 U/ml alkaline phosphatase, and 0.2mM Amplex Red. For acidic SMase (A-SMase), the reaction was carried out in an acidic buffer of 50mM sodium acetate (pH 5.0) containing 0.5mM SM without Mg 2þ , and then the reaction was detected with Amplex reagents mixed in 100mM Tris-HCl (pH 8.0, to bring up pH to the optimal point for Amplex reagents). The excitation and emission wavelengths were 560 and 590 nm, respectively. The reaction was linear in a range of up to 160 lg protein for 30 min incubation of the sample with reaction buffer at 37°C. In all experimental reactions for SMase assay, the samples were allowed to incubate with reaction buffer for 20 min at 37°C. SMase contents were calculated based on a standard curve prepared parallel to sample reactions. The standard curve was in linear range up to 10 mU/ml of SMase in the reaction buffer.
The protein contents were determined by Bradford reagent according to the manufacturer's protocol (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin (BSA) as a standard.
Expression of genes for SPT and SPHK. Gene expression of SPT subunits (LCB1 and LCB2) and SPHK isoforms (SPHK1 and SPHK2) in liver was analyzed by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR). The frozen tissue was homogenized in TRI reagent (Molecular Research Center, Cincinnati, OH). The first-strand cDNA was synthesized using SuperscriptIII reverse transcriptase and Oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer (InVitrogen Life Technologies, Carsbad, CA). The abundance of mRNA for selected genes in liver tissues was analyzed by PCR using Taq DNA polymerase and 0.2lM of each primer in 13 PCR buffer containing 2mM MgCl 2 . The PCR reactions were performed in an Eppendorf Mastercycler Gradient (Eppendorf Scientific Inc., Westbury, NY). Table 1 shows the sequences of primers (chosen by Primer3 program, Whithead Institute, Cambridge, MA) for respective genes and conditions employed for amplification reaction. The PCR products were separated on 2% agarose gel containing ethidium bromide and detected by an ultraviolet transilluminator (Ultra Lum Inc., Carson, CA). Images were captured using a Kodak DC290 camera followed by digitization using UN-SCAN-IT software (Silk Scientific Inc., Orem, UT). Density of bands for b-actin in the same sample was used to normalize the expression of each gene. The quantitative validity of RT-PCR has been confirmed by either northern blot in lipopolysaccharide (LPS)-treated J774.A macrophages (He et al., 2001) or ribonuclease protection assay in mouse liver (Bhandari and Sharma, 2002) .
Protein levels of SPT and SPHK. Frozen liver tissues were homogenized in lysis buffer (20mM Tris-HCl pH 8.0, 137mM NaCl, 2mM ethylenediaminetatraacetate [EDTA], 10% glycerol, 1% Triton X-100, 100lM dithiothreitol, 1mM sodium orthovanadate, 20lM phenylmethylsulfonyl fluoride, and 10lg/ml of each leupeptin and aprotinin). Lysates were centrifuged for 30 min at 42,000 3 g, and supernatants were collected for Western blot analysis after quantifying protein concentrations. An aliquot of 10 lg protein from each sample was subject to electrophoresis on polyacrylamide gels containing 10% sodium dodecylsulfate and then transferred to polyvinylidene difluoride membranes. Equal loading and transfer of protein was confirmed by staining the membranes with reversible Ponceau S before incubation with respective primary antibodies. Proteins were detected with polyclonal antibodies, against LCB1, LCB2, and SPHK1, respectively, using enhanced chemiluminescence detection kit (Amersham Pharmacia, Piscataway, NJ). The exposure time of the film was optimized to be in the linear range before the saturation occurs.
Activity of SPT. The activity of SPT in liver was analyzed using the method described earlier (Williams et al., 1984) with minor modification. Briefly, the frozen tissues were homogenized in homogenization buffer (50mM N-(2-hydroxyethyl)piperazine-N#-(2-ethanesulfonic acid), 5mM DLdithiothreitol, 10mM EDTA, and 0.25M sucrose, pH 7.4), and homogenates were centrifuged at 30,000 3 g for 30 min. Aliquots of 50 lg protein in the supernatant were used for analysis of SPT activity, as described (Williams et al., 1984) Activity of SPHK. The activity of SPHK in liver homogenate was estimated according to the method described previously (Olivera et al., 2000) . The protein extract (50 lg protein for each reaction) from liver homogenate was incubated in reaction buffer (20mM Tris, pH 7.4, 20% glycerol, 1mM mercaptoethanol, 1mM EDTA, 1mM sodium orthovanadate, 40mM b-glycerophosphate, 15mM sodium fluoride, 1mM phenylmethylsulfonyl fluoride, and 10 lg/ml of each leupeptin Other PCR conditions included hot start at 95°C for 5 min, one cycle, followed by denaturing at 94°C for 30 s, annealing at indicated temperatures for 30 s, elongation at 72°C for 1 min for indicated cycles, and finally elongation at 72°C for 1 min, 1 cycle. The conditions were optimized to keep the number of cycles within the range of exponential increase of amplified products. and aprotinin) containing 50lM sphingosine as a sphingosine-BSA complex in a total volume of 190 ll. The reaction was started by adding 10 lCi of c-32 P-ATP (10 ll, 20mM, Amersham) containing MgCl 2 (200mM) and incubated for 15 min at 37°C. The labeled lipids in the organic phase were resolved by thinlayer chromatography on Silica Gel G60 (EMD Chemical, Gibbstown, NJ). Conditions to ensure linearity of the enzymatic reaction with time of incubation and protein concentration were optimized in preliminary trials.
Gene expression of SPT and SPHK in liver regeneration after acetaminophen treatment. Since the response to fumonisin B 1 in mice includes cell damage and hepatic regeneration Sharma et al., 2003) , the expression of SPT and SPHK during regeneration was determined after treatment of female mice with acetaminophen (a well-known hepatotoxicant) injections. In a separate experiment, groups of five female mice each, similar to ones as above, were injected with 2.25 mg/kg fumonisin B 1 sc or with 200 mg/kg of acetaminophen (10 mg/ml at 40°C) in PBS ip once daily for 5 days. Concurrent control groups for both fumonisin B 1 and acetaminophen were injected with PBS using the route similar to the respective treatments. Animals were sampled one day after, and hepatocyte proliferation was evaluated in liver sections by expression of proliferating cell nuclear antigen (PCNA) as described earlier . The expression of LCB1, LCB2, and SPHK1 in liver was determined by RT-PCR as indicated above.
Statistical analysis. Results are presented as mean ± SE. Data were analyzed by one-way ANOVA followed by Duncan multiple range tests unless otherwise stated in the text. All statistical analyses were done using the SAS program (SAS, Cary, NC). The level of p < 0.05 was considered significant.
RESULTS

Treatment with Fumonisin B 1 Caused Liver Damage
Treatment of the animals with fumonisin B 1 for 5 days did not cause changes in body weights and liver weights and in the ratio of liver over body weight (data not shown). The treatment resulted in 4-to 20-fold increases in activities of plasma ALT and AST compared to the saline-treated controls (Table 2) , indicating liver injury. The hepatic damage was also confirmed by the increased number of apoptotic hepatocytes detected with TUNEL staining on liver sections (Table 2) . For most parameters, however, there seemed to be a threshold at 0.75 mg/kg dose after which there was no remarkable increase in the effects.
Accumulation of Free Sphingoid Bases in Liver Following
Fumonisin B 1 Treatment
It is known that ceramide synthase inhibition following fumonisin B 1 exposure results in accumulation of free sphingoid bases. After five daily treatments of mice with fumonisin B 1 , the dose-dependent increases of hepatic free sphingosine and sphinganine leveled of at the middle dose of 2.25 mg/kg (Table 3) .
Alteration of SM and SMase in Liver
SM can be metabolized to ceramide by SMase. It is known that ceramide synthase inhibition by fumonisin B 1 reduced both ceramide and SM in cells . To see whether SM and SMase could be affected following a shortterm exposure of mice to fumonisin B 1 in vivo, the content of SM and activity of SMase were analyzed. Results showed that hepatic SM was reduced about 60% compared to controls in response to fumonisin B 1 , with maximum decrease again at the lowest dose. A dose-dependent increase in activities of ASMase was observed with a significant increase at the highest dose of fumonisin B 1 (Fig. 2) . The changes of N-SMase in response to fumonisin B 1 were not significant.
Increase of Hepatic SPT and SPHK Gene Expression Following Fumonisin B 1 Treatment
We have reported that fumonisin B 1 treatment increased activity of liver SPT . To explore the possible mechanisms for the induction of SPT following fumonisin B 1 -induced ceramide synthase inhibition, we analyzed the expression of SPT in liver. The gene expression of LCB1 and LCB2, two subunits of SPT, was significantly increased (Fig. 3) . It has been reported that fumonisin B 1 increased 1-phosphate metabolites of free sphingoid bases . The increase in sphingoid base-1-phosphate could result from increased input of free sphingoid bases per se, or activation of SPHK, or both. It was therefore of interest to determine if fumonisin B 1 treatment could alter SPHK expression. Results showed that gene expression of SPHK1 increased significantly in response to fumonisin B 1 treatments, with the increase reaching its maximal at the lowest dose of 0.75 mg/kg employed here (Fig. 4) . In contrast, expression of SPHK2 was not affected by fumonisin B 1 treatment.
Levels of SPT Subunits and SPHK1
Levels of SPT subunits and SPHK1 determined by Western blots are depicted in Figures 5 and 6 . Since gene expression of 
Activities of SPT and SPHK Increased with the Protein Expression
Consistent with increases in protein expression, the activities of both SPT and SPHK were increased after fumonisin B 1 treatment in mouse liver (Fig. 7) . Again, there was a lack of dose-response relationship for both enzyme activities. Similar to the increases of protein levels, the activities of both enzymes reached their highest levels at 0.75 mg/kg; however, the increases were about fourfold and twofold of controls for SPT and SPHK, respectively.
Induction of SPT and SPHK Was Not Due to Hepatic Regeneration
Mice injected with acetaminophen showed proliferation of PCNA-positive hepatocytes similar to that observed with fumonisin B 1 and also described earlier Sharma et al., 2003) ; however, no effect of acetaminophen treatment was observed on the expression of LCB1, LCB2, or SPHK1 (Fig. 8) .
DISCUSSION
The current study demonstrated that treatment of mice with fumonisin B 1 , a reportedly specific inhibitor of ceramide synthase, enhanced activities of liver SMase, SPT, and SPHK leading to compensatory changes in sphingolipids and/or further perturbation of sphingolipid metabolism. Fumonisin B 1 caused inhibition of sphingolipid biosynthesis, leading to accumulation of free sphingoid bases and decreases in ceramide, SM, and complex sphingolipids, as reported in a variety of previous studies (Merrill et al., 1993; Wang et al., 1991; Yoo et al., 1996) . The important novel findings in the current study are that expression and activities of SPT and SPHK were upregulated following fumonisin B 1 treatment. This upregulation apparently was not a consequence of increased hepatic regeneration in response to fumonisin B 1 toxicity, as treatment with a known hepatotoxicant, acetaminophen, induced liver regeneration demonstrated by an increase in PCNA in liver but did not induce the same effects on SPT and SPHK. Hepatic regeneration was accompanied by an increase of SM synthase activity during the first 18 h with a subsequent decrease of SM synthase and increase of SMase at 24 h following hepatectomy (Albi et al., 1999) . It is unknown whether liver regeneration in partial hepatectomy affects SPT 1.02 ± 0.24 29.00 ± 8.32** 71.12 ± 8.24** 60.01 ± 11.3** Sphingosine (pmol/mg tissue)
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FIG. 2.
Effects of fumonisin B 1 on SM contents and SMase activity in mouse liver following five daily fumonisin B 1 treatments. Mean ± SE, n ¼ 5. *p < 0.05 compared to the control (0 mg/kg fumonisin B 1 ) group. or SPHK. However, the cellular mechanisms of tissue regeneration under different conditions may be different, thus, contributing to the observed disparities.
The exact mechanisms of observed effects in this study are yet to be investigated. Enzymes that regulate bioactive lipids function as switches by regulating the levels of bioactive substrates and products (Hannun et al., 2001) and, therefore, regulate cellular signal transduction. Ceramide can be generated through SM hydrolysis by SMase. Ceramide is essential to cells and a decrease in intracellular ceramide as a result of de novo biosynthesis inhibition by fumonisin B 1 could increase the activity of SMase to compensate for reduced cellular ceramide level by production of ceramide via SM hydrolysis. In mice treated with similar doses of fumonisin B 1 , no decrease of ceramide was noticed (Tsunoda et al., 1998) , suggesting that stimulation of A-SMase activity compensated the generation of ceramide following ceramide synthase inhibition. In cell signaling involving ceramide, the A-SMase appears to be more important; L929 fibrosarcoma cells deficient in A-SMase were resistant to ceramide-mediated caspase-independent apoptosis (Thon et al., 2005) .
A noteworthy observation here is that the effects of fumonisin B 1 treatment on SPT and SPHK were maximized at the lowest dose, whereas the accumulation of sphinganine or sphingosine in liver was dose related only up to 2.25 mg/kg of fumonisin B 1 . At the highest dose of 6.75 mg/kg fumonisin B 1 , no further increase in sphinganine or sphingosine accumulation was observed. Previous studies have shown that the IC 50 of fumonisin B 1 for inhibition of labeling sphingosine in hepatocytes or SM in neurons were 0.1lM and 0.7lM, respectively (Merrill et al., 1993; Wang et al., 1991) . Treatment of hepatocytes with 1lM fumonisin B 1 reached an almost (Wang et al., 1991) . Based on homogenous distribution in the tissues, the sc injection of fumonisin B 1 at 0.75 mg/kg daily for 5 days could reach approximately the concentration for complete inhibition of ceramide synthase. Over 1 lg fumonisin B 1 /g tissue (~1.4 lmol fumonisin B 1 /kg tissue) was detected in liver of pigs 72 h after iv injection of 0.4 mg fumonisin B 1 /kg body weight (Prelusky et al., 1994) . Whereas the maximal effect on SM concentration was observed at 0.75 mg/kg of fumonisin B 1 , the induction of SPT and SPHK reached a plateau at the lowest dose employed here. It may be inferred that either the maximal induction of SPT and SPHK required only a small increase in the levels of free sphingoid bases, or alternatively, the increase in these enzymes is independent of the accumulation of sphinganine and/or sphingosine. Other factors such as de novo biosynthesis inhibition of ceramide and/or gangliosides, and defective cellular responses resulting from cytotoxicity, as demonstrated in the current study that plasma activities of ALT and AST reached maximum at the lowest dose (0.75 mg/kg/ day), may be responsible for the lack of a dose-response effect on these sphingolipid-metabolizing enzymes.
In the current study, the activity of SPT paralleled the increased expression of respective protein, suggesting that the induction of SPT is due to increased enzyme synthesis. In response to LPS and cytokines, such as tumor necrosis factor (TNF)-a and interleukin (IL)-1, the production and activity of SPT was increased with subsequent increase of sphingolipid biosynthesis in liver of Syrian hamster and HepG2 cells (Memon et al., 1998) . In our previous studies, we have consistently observed that fumonisin B 1 increased the expression of many cytokines including TNF-a (Bhandari and Sharma, 2002; He et al., 2001) . The increase in SPT production following fumonisin B 1 treatment may be related to the induction of TNF-a and other cytokines.
SPHK catalyzes phosphorylation of sphingosine to form sphingosine-1-phosphate, a key cell signal modulator . It is known that fumonisin B 1 treatment significantly increased formation of sphinganine-1-phosphate . Recently, we reported that SPHK was an important factor in resistance to fumonisin B 1 cytotoxicity in HEK 293 cells, a human embryonic cell line . Since fumonisin B 1 produces cellular apoptosis and proliferation Howard et al., 2001b; Jones et al., 2001; Sharma et al., 1997) , the activation of SPHK and subsequent formation of sphingoid base-1-phosphate following FIG. 6 . Levels of SPHK1 in liver aliquots after treatment of mice with fumonisin B 1 , determined by Western blotting. The levels are shown as fold of control value. Levels of SPHK2 were not determined as there was no increase in gene expression for this isoform. Mean ± SE, n ¼ 5. *p < 0.05 compared to the control (0 mg/kg fumonisin B 1 ) group. fumonisin B 1 treatment could contribute to the cell proliferation needed for liver regeneration. In addition to inhibition of ceramide synthase and subsequent blockade of ceramide formation, generation of sphingoid base-1-phosphate as a result of SPHK induction might partly involve the protective effect of fumonisin B 1 in stress-induced apoptosis (Reiss et al., 2004) . SPHK can be activated by various external stimuli including growth factors, TNF-a, IL-1b, and many others . It has been reported that TNF-a could interact with TNF-receptor-associated factor 2 to activate SPHK with subsequent production of sphingosine-1-phosphate (Xia et al., 2002) and thus protect cells from apoptotic death (Osawa et al., 2001; Xia et al., 1999) . Exposure of animals to fumonisin B 1 increases free sphingoid bases as well as TNF-a production (He et al., 2001; Riley et al., 2001; Sharma et al., 2003) . It is plausible that either sphingoid bases or TNF-a stimulates expression of SPHK since TNF-a is known to activate SPHK and NFjB, an important transcriptional factor.
FIG. 7.
Activities of SPT and SPHK in mouse liver following five daily fumonisin B 1 treatments. Mean ± SE, n ¼ 5. *p < 0.05 compared to control (0 mg/kg fumonisin B 1 ) group.
FIG. 8.
Hepatic cell proliferation and expression of SPHK and SPT after treatment of mice with acetaminophen compared to that of fumonisin B 1 . Groups of mice were treated with either 200 mg/kg acetaminophen or 2.25 mg/kg fumonisin B 1 , and liver aliquots were analyzed as indicated in methods. Mean ± SE, n ¼ 5. *p < 0.05 compared to respective saline-treated control group.
FUMONISIN ALTERS SPHINGOLIPID METABOLISM
The observed changes in hepatic expression of SPT and SPHK following fumonisin B 1 administration may be relevant in cellular signaling and function. While the accumulated free sphingoid bases are generally apoptotic, their respective phosphates impart cell survival properties Spiegel and Milstien, 2002) . Activation of SPHK leading to sphingoid base-1-phosphate production may partially counteract the cell death signals by fumonisin B 1 -induced sphingoid bases accumulation and may be necessary for tissue repair. The observations here therefore emphasize the complexity of lipid signaling and paradoxical effects produced by fumonisin B 1 or resulting alterations in sphingolipid metabolism.
In summary, fumonisin B 1 treatment increased activities of SPT and SPHK in mouse liver; the increases in activities of SPT and SPHK could be explained by upregulation of their transcriptional and translational levels. The events observed here may be related in part to the reported effects of fumonisin B 1 on apoptosis, cell cycling , or tissue regeneration. Current study indicates that interference with one step of sphingolipid metabolism (ceramide synthase inhibition) could affect other metabolizing enzymes leading to further regulation of sphingolipid homeostasis.
